Tag: voretigene neparvovec

Spark Therapeutics bags Luxturna EU approval for inherited retinal disease

pharmanewsdaily- November 24, 2018

Luxturna EU approval for inherited retinal disease : Pennsylvania-based Spark Therapeutics has bagged the European Commission’s (EC) approval for its gene therapy Luxturna (voretigene neparvovec) ... Read More